Trial Profile
Phase II Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms FRAIL
- 26 Mar 2014 Planned End Date changed from 1 Feb 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 19 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2012 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.